Seeking Alpha

Questcor Pharmaceuticals (QCOR) acquires Canadian biotech firm BioVectra for C$50M. BioVectra is...

Questcor Pharmaceuticals (QCOR) acquires Canadian biotech firm BioVectra for C$50M. BioVectra is a contract manufacturing services provider to the global pharmaceutical and biotechnology industry and manufactures active pharmaceutical ingredients, chemical intermediates, and bioprocessing reagents. The acquisition is part of a larger strategy by QCOR to lock down a key ingredient maker for its only drug, Acthar, which isn't patent-protected, and will help to protect the drug's manufacturing process trade secrets.
Comments (6)
  • PeakOiler
    , contributor
    Comments (296) | Send Message
     
    Check the news on QCOR. Seems that Acthar doesn't have much of a future given the drug is widely available in generic form for peanuts.
    2 Jan 2013, 06:54 PM Reply Like
  • Michael Bryant
    , contributor
    Comments (5581) | Send Message
     
    Old news.
    2 Jan 2013, 09:35 PM Reply Like
  • wadeyr
    , contributor
    Comments (199) | Send Message
     
    where is your evidence?
    3 Jan 2013, 04:30 AM Reply Like
  • drdon
    , contributor
    Comments (201) | Send Message
     
    Peak you obviously know peanuts about QCOR. Get your facts in order before presenting innuendos and mistruths from sources that are obviously shorts.
    2 Jan 2013, 10:34 PM Reply Like
  • wadeyr
    , contributor
    Comments (199) | Send Message
     
    good decision
    3 Jan 2013, 04:54 AM Reply Like
  • Ernest P Icahn
    , contributor
    Comments (378) | Send Message
     
    Spending up to $100M for a Low Margin Business just to protect secrets? They have the sales-force, cudda bot a whole other pipeline, Dummies!
    4 Jan 2013, 11:38 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector